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E-cadherin is a transmembrane protein in epithelial cell–cell inter-
actions at adherence junctions and is linked with the cytoskeletal
matrix through interactions with a-catenin (Gumbiner and
McCrea, 1993; Breen et al, 1995). The expression of the homo-
typic cell adhesion molecule E-cadherin is reduced in many types
of cancer (Morton et al, 1993, 1995; Rimm et al, 1995; van der
Wurff et al, 1997). The loss of this protein may be associated with
metastasis because alteration of its function is required for
invasion in vitro (Behrens et al, 1989; Frixen et al, 1991;
Vleminckx et al, 1991; Breen et al, 1995). The decreased expres-
sion has also been related to more aggressive tumour behaviour in
vivo (Rimm et al, 1995; Paul et al, 1997; Richmond et al, 1997;
van der Wurff et al, 1997). It is likely that the loss of downstream
effector elements in the cadherin adhesion cascade (Gumbiner
et al, 1993; Breen et al, 1995) may also disrupt cell–cell inter-
actions and thereby promote invasion, but direct evidence is still
scanty. One such effector element is a-catenin (Gumbiner et al,
1993; Breen et al, 1995), a cytoplasm protein related to vinculin
that is associated in vivo with E-cadherin. Catenins play an impor-
tant role in the dysfunction of the cell adhesion complex and
mechanisms of inactivation of the cadherin–catenin pathway
include LOH (loss of heterozygosity), gene deletions and gene
promoter hypermethylation (Morton et al, 1993; Vermeulen et al,
1996; Crundwell et al, 1997).
Previous studies indicate that E-cadherin expression correlates
inversely with tumour grade and stage in various cancers (Breen
et al, 1995; Rimm et al, 1995; van der Wurff et al, 1997), including
prostate cancer (Umbas et al, 1994; Crundwell et al, 1997; Murant
et al, 1997; Paul et al, 1997; Richmond et al, 1997), and it seems to
have prognostic value (Umbas et al, 1994; Richmond et al, 1997).
The significance of a-catenin is not completely understood in
prostate cancer progression (Crundwell et al, 1997; Murant et al,
1997; Paul et al, 1997; Richmond et al, 1997; Umbas et al, 1997).
Initial studies (Crundwell et al, 1997; Richmond et al, 1997)
based on small number of prostate cancer cases, reveal that up to
40% of the tumours may show abnormal a-catenin expression. In
addition, this down-regulation correlates to disease progression
(Crundwell et al, 1997; Richmond et al, 1997; Umbas et al, 1997).
Prompted by the above mentioned observations (Crundwell et al,
1997; Shimazui et al, 1997; Umbas et al, 1997; Zsciesche et al,
1997) we (a) analysed the expression of a-catenin in unselected
large series of prostate cancer and (b) related the results to other
known prognostic factors and patient survival.
MATERIALS AND METHODS
Patients
The current study comprised 215 patients with prostate cancer
diagnosed and treated at the Department of Urology, Kuopio
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expression had independent prognostic value in T1–2 M0 tumors. In the M0 tumours, abnormal a-catenin signal was independently
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provide prognostic information in early prostate cancer.
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tion period was 13 years [standard deviation (s.d.) 3, range 8–21]
and the mean age of patients at presentation was 72 years (s.d. 8,
range 40–89). The cohort was not entirely consecutive since
sufficient tumour specimens for immunohistochemistry were
not available in all cases. Tumour-metastasis classification
was done according to UICC standards (UICC, 1978). Radical
prostatectomy was rarely done during the study period, which
explains why the node (N) classification was not available. The
patients were treated by orchiectomy in 100 cases, other endocrine
therapy was used in 70 cases, radical prostatectomy or radiation
therapy was done in nine cases and careful follow-up only was
used in 76 cases. The follow-up reviews were done at 3-month
intervals during the first 2 years, and thereafter at 6-month inter-
vals. At the time of diagnosis, 61/215 (28%) cases had distant
metastasis. The causes of death were verified from the patient
files, autopsy reports and from the files of Finnish Cancer
Registry.
Histological methods and flow cytometry
The histological samples were core needle biopsies or TURP
specimens fixed in buffered formalin (pH 7.0), embedded in
paraffin, sectioned at 5mm and stained with haematoxylin and
eosin. The histological differentiation of tumours was evaluated
as described by Gleason (1977). The perineural growth was
categorized into two groups; present or absent. The mitotic figures
were identified and calculated from the most actively proliferating
area in the section (Vesalainen et al, 1995). The volume corrected
mitotic index method (M/V index) was used, which expresses the
number of mitotic figures/square millimetre of tumour tissue in the
section (Vesalainen et al, 1995). The results of flow cytometry
have been reported in detail previously (Vesalainen et al, 1994).
DNA index was available in 182/215 (85%) of cases and S phase
fraction in 175/215 (81%) of cases.
a-Catenin immunohistochemistry
Five-micrometre-thick sections from the primary tumours were
deparaffinized, rehydrated and washed twice for 5min with
phosphate-buffered saline (PBS). For a-catenin analysis, the
sections were heated in a microwave oven in 0.005MHCl
(pH = 9.7) for 2 ´5min.
Endogenous peroxidase activity was blocked with 5% hydrogen
peroxide for 5min, followed with a wash for 2 ´5min with PBS.
The tissue sections were incubated overnight at 4°C with a
primary mouse monoclonal anti a-catenin antibody (Transduction
Laboratories, Lexington, KY, USA) at a working dilution of 1:100.
Sections were washed twice for 5min with PBS and incubated for
30min using a biotinylated secondary antigen (Vectastain ABC
Elite kit, Vector Laboratories, CA, USA) diluted 1:200 in PBS.
Slides were washed twice in PBS for 2 ´5min and incubated for
40min in preformed avidin–biotinylated peroxidase complexes
(Vectastain ABC Elite kit, Vector Laboratories, CA, USA).
Sections were washed twice for 5min with PBS, developed for
5min with 0.05% 3,3-diaminobenzidine tetrahydrochloride
(DAB) (Sigma, UK), slightly counterstained with haematoxylin,
dehydrated, cleared and mounted with DePex (BDH, Limited
Poole, UK). In each staining batch, normal epithelium served as a
positive control. In negative controls, primary antibody was
omitted.
Scoring of immunohistochemistry
The expression of a-catenin in cancer cells was compared with
that of normal epithelial cells in the sample. First, the intensity of
the staining was scored as follows: negative (0), weak (1) or strong
(2). Cancer cells which stained as strong as the normal prostate
epithelium were defined as normal expressors (strong intensity).
Weak expression was defined as a faint staining clearly weaker
than that in normal epithelium. Secondly, the localization of
staining signal was categorized into two groups: staining along the
cell membranes and cytoplasmic involvement in addition to
membranous staining. Finally, the staining signal was graded
according to the proportion of positive cancer cells. The fraction of
positive cancer cells (%) was primarily analysed in a continuous
scale, but for statistical calculations, tumours having over 95%
cancer cells positively stained were considered as positive
(normal). The others were considered as abnormal. In the scoring
process, only well-preserved tumour tissue was evaluated. It
became evident that in TURP specimen the chip margins
frequently showed no a-catenin signal, probably due to tissue
denaturation and coagulation during TURP procedure. To validate
the above described scoring principle, a test set of 48 prostatec-
tomy sections were analysed to test the frequency of abnormal
a-catenin expression in surgically removed tissues.
Statistical analysis
In the basic statistical calculations, the SPSS-X program package
was used in an IBM computer and the statistical tests used are
indicated in connection with the results when appropriate.
Univariate survival analysis (log-rank analysis) was based on a
life-table method with statistics by Gehan (SPSS-X). Multivariate
survival analysis (Cox’s analysis) used deaths from prostate cancer
as events. Multivariate analysis was done in two phases. The first
analysis included TM-categories, Gleason score and the a-catenin
indices. The second analysis included all the available parameters.
RESULTS
Normal and hyperplastic prostate epithelium in the close vicinity
of tumours showed strong positive staining along cell membranes
throughout the cell–cell boundaries. The intensity of staining was
strong (normal) in 190 (88%) tumours (Figure 1A) and weak in 19
(9%) tumours. Six tumours (3%) were completely negative for
a-catenin (Figure 1B). Staining pattern along cell membranes was
observed in 189 (88%) cases and additional cytoplasmic involve-
ment (Figure 1C) was present in 20 cases (9%). The staining was
regarded abnormal (positive tumour cells less than 95% of the
total tumour cell population) in 39 (18%) cases. The test set treated
by surgical prostatectomy revealed one a-catenin negative case
(2%) and seven cases (15%) with less than 95% of positive cells.
These figures correspond to those found in the main series of
prostate cancer cases.
Both cytoplasmic involvement (c2 = 89, P< 0.001) and weak
staining intensity (c2 = 59, P< 0.001) were related to abnormal
a-catenin expression (positive cells less than 95%). In addition,
weak intensity was significantly associated with high grade
(P= 0.006) and T3–T4 categories (P= 0.0007), but not with other
analysed cellular features. The negative staining, as well as the
cytoplasmic localization of a-catenin, were linked with high T
classification, high grade, presence of perineural infiltration, DNA
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metastasis (Table 1). The reduced expression of a-catenin
(positive cells less than 95%) was related to several prognostic
factors as detailed in Table 2. In the test set of prostate cancers,
all the cases with abnormal a-catenin expression belonged to
pT3A–pT3C categories, except one case which was pT4. The
Gleason score was over 6 in six of the cases with abnormal
a-catenin expression.
In the univariate survival analysis, cytoplasmic signal in addi-
tion to membranous staining predicted unfavourable patient
outcome (Figure 2). The reduced expression was associated with
lowered survival probability in the entire series with a borderline
significance (Figure 3). However, it had no statistically significant
prognostic value either in M0 (P = 0.2) or in T1–2 M0 tumours
(Figure 4).
In the multivariate analysis including TM-classification,
Gleason score and a-catenin indices, abnormal a-catenin staining
had independent prognostic value only in T1–2 M0 tumors
(Table 3). Recurrence-free survival of M0 tumors was indepen-
dently related to T-category (relative risk (RR) = 1.74, 95%
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Table 1 The significant relationship between the localization of a-catenin
signal and various prognostic factors in prostate cancer
a-catenin localization in tumour epithelium
Negative Cytoplasmic and Membranous P-value
membranous staining
staining
T1 0 9 81 < 0.001
T2 1 5 40
T3 1 12 45
T4 4 13 10
M0 3 23 131 0.009
M1–2 3 16 45
Gleason score 2–4 0 2 10 < 0.001
5–7 1 6 95
8–10 5 31 71
PNI negative 0 10 70 0.003
positive 2 14 36
M/V index ≤ 7 2 18 114 0.002
> 7 4 21 57
Diploid 2 14 91 0.008
Aneuploid 4 21 56
S phase ≤ 5% 1 8 69 0.003
Fraction > 5% 5 27 71
PNI = perineural growth; M/V index = volume corrected mitotic index.
 
 
 
Figure 1 (A) A prostate cancer showing strong normal membranous
expression of a-catenin (magnification 250x). (B) A poorly differentiated
a-catenin-negative prostate cancer (magnification 250´). (C) A poorly
differentiated prostate cancer shows both cytoplasmic and membranous
staining pattern of a-catenin (magnification 250´)
Table 2 The significant relationship between the expression of a-catenin
and various prognostic factors in prostate cancer
Normal Abnormal P-value
a-catenin a-catenin
expression expression
T1 81 9 <0.001
T2 40 5
T3 45 12
T4 10 13
M0 131 23 0.05
M1–2 45 16
Gleason score 2–4 10 2 <0.001
5–7 95 6
8–10 71 31
PNI negative 70 10 0.02
positive 36 14
M/V index ≤ 7 114 18 0.02
> 7 57 21
Diploid 91 14 0.02
Aneuploid 56 21
S phase ≤ 5% 69 8 0.004
Fraction > 5% 71 27
M/V index = volume corrected mitotic index; PNI = perineural growth.confidence interval (CI) 1.27–2.39, P < 0.001), DNA aneuploidy
(RR = 3.41, 95% CI 1.74–6.69, P < 0.001) and the staining
intensity of a-catenin (RR = 0.51, 95% CI 0.29–0.89, P = 0.017).
If all the analysed features (T-category, presence of metastases,
Gleason grade, perineural infiltration, mitotic index, DNA ploidy
and S phase fraction) were entered in the model, independent
prognostic factors in the entire series were M-category (RR = 3.12,
95% CI 1.78–5.46, P = 0.0002), T-category (RR = 1.75, 95% CI
1.33–2.29, P = 0.0001) and M/V index (RR = 1.02, 95% CI
1.00–1.05, P = 0.041). In M0 tumours, independent predictors
were T-category (RR = 1.59, 95% CI 1.12–2.24, P = 0.005) and
Gleason score (RR = 3.30, 95% CI 1.43–7.60, P = 0.005). Finally,
in clinically local T1–2 M0 tumours, Gleason score (RR = 3.08,
95% CI 1.15–8.21, P = 0.024) and M/V index (RR = 1.06, 95%
CI 1.01–1.12, P = 0.009) were independent prognostic factors of
survival.
DISCUSSION
Normal and hyperplastic prostatic epithelium revealed normal,
strong and uniform staining pattern of a-catenin, whereas in
cancer tissue various a-catenin staining signals were frequently
detected. The a-catenin expression was abnormal in 18% of the
cases in the main series. Consequently, 15% of cases in the test set
treated by prostatectomy showed similar reduced a-catenin signal.
In a heterogenous group of prostate cancers, Richmond and
co-workers (Richmond et al, 1997) reported up to 41% of the
tumours (33/79 cases) showing abnormal a-catenin expression
which is a higher figure than ours. Another previous study with
local incidentally detected tumours reported that the proportion of
abnormal  a-catenin expression was over 40% (10/23 cases)
(Crundwell et al, 1997). Both of these studies have utilized TURP
specimens for immunohistochemistry but no description is given
whether all the tumour tissue was used in the scoring process.
According to our experience, it is highly important to exclude the
TURP chip margins from evaluation since the tissue damage due
to heating seems to abolish a-catenin immunoreactivity.
Additional support for this comes from our test set (surgical
prostatectomy specimens) which showed a similar frequency
distribution of a-catenin as the main series. We believe that this
notion seems to validate the adopted scoring principle. Similar
results have also been reported by Umbas and co-workers (Umbas
et al, 1997), since they observed aberrant a-catenin expression in
52% of the heterogeneous group of prostate tumours, while in their
small radically operated group of tumours only 20% (4/20) of the
cases showed abnormal a-catenin expression (Umbas et al, 1997).
There was a significant relationship between the reduced
a-catenin expression and high Gleason score, suggesting more
aggressive behaviour and increased potential to spread locally and
to distant sites. A similar relationship between high grade and
a-catenin abnormalities has been previously reported both in
prostate cancer (Richmond et al, 1997) and in other epithelial
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Figure 2 The survival of patients categorized according to the localization
of a-catenin signal (P = 0.04, c2 = 6). Curve A: membranous staining,
n = 188; Curve B: membranous and cytoplasmic staining pattern, n = 20;
Curve C: negative staining, n = 6
Figure 3 The survival of patients categorized according to the expression
of a-catenin. The curves are almost significantly separated (P = 0.06,
c2 = 3.5). Curve A: a-catenin normal, n = 176; Curve B: a-catenin
abnormal, n = 39
Figure 4 The survival of patients with a T1–2 M0 tumour categorized
according to the expression of a-catenin (P = 0.1, c2 = 2.6). Curve A:
a-catenin normal, n = 121; Curve B: a-catenin abnormal, n = 14
Table 3 The independent prognostic factors in the entire cohort and in non-
metastatic as well as in clinically local tumours
b (s.e.) P-value RR (95%Cl)
T1–4 M0–1 tumours
M-category 1.11 (0.25) < 0.001 3.04 (1.83–5.04)
T-category 0.46 (0.13) < 0.001 1.59 (1.22–2.07)
Gleason score 0.55 (0.25) 0.026 1.74 (1.06–2.85)
T1–4 M0 tumours
T-category 0.59 (0.16) < 0.001 1.81 (1.32–2.49)
Gleason score 0.75 (0.34) 0.028 2.12 (1.08–4.14)
T1–2 M0 tumours
T1 vs T2 1.73 (0.40) < 0.001 5.68 (2.57–12.56)
a-Catenin expression –1.06 (0.51) 0.037 0.34 (0.12–0.93)neoplasms (Rimm et al, 1995; Shimazui et al, 1997; van der Wurff
et al, 1997). a-catenin abnormalities were frequently detected in
tumours showing perineural growth which indicates that a-catenin
abnormalities also favour invasive growth in vivo. The significant
relationship between a-catenin abnormalities and all proliferation
indices found in this study is in line with the inter-relationship
between Gleason score and a-catenin abnormalities (Richmond
et al, 1997).
The presence of metastasis and local spread were related to
reduced  a-catenin expression. Abnormalities in the staining found
in our T1–T2 tumours were rare but the frequency clearly
increased in T3–T4 tumours. Similarly, in the test set of tumours
treated by prostatectomy, the final histopathological analysis of the
prostatectomy specimens (pT) revealed that all the tumours
showing down-regulation of a-catenin belonged mostly to
pT3A–C categories. These results suggest that tumours with
reduced  a-catenin expression rapidly progress locally into inva-
sive disease. It is obvious that the metastatic potential of prostate
tumours is not dependent on cell adhesion factors alone, and many
other factors including the host response are involved (Vesalainen
et al, 1994). In alignment with our notion, the relationship between
a-catenin expression and tumour spread has been reported previ-
ously in prostate cancer (Richmond et al, 1997) and in tumours of
the urinary tract (Shimazui et al, 1996).
The earlier studies in prostate cancer indicate that a-catenin
abnormalities predict unfavourable prognosis (Richmond et al,
1997; Umbas et al, 1997). In our study, abnormal signal localiza-
tion as well as down-regulation of a-catenin were related to
unfavourable prognosis supporting these previous findings
(Richmond et al, 1997; Umbas et al, 1997).
Since several genetic changes occur simultaneously in prostate
cancer (Isaacs, 1995), only multivariate analysis of prognostic
factors can give insight to the impact of individual prognostic
factors on patient survival. In the current study abnormal a-catenin
expression was an independent prognosticator only in T1–2 M0
group of tumours and when Gleason score, T-classification and
different a-catenin indices were included in the analysis. In a
subgroup analysis of M0 cases, reduced a-catenin signal was
independently related to early recurrence. Umbas and co-workers
(Umbas et al, 1997) reported that all four cases out of 20 patients
treated by radical prostatectomy and having aberrant expression of
a-catenin recurred, while those tumours with normal expression
had no recurrence within 40 months follow-up. In another study
a-catenin had significant prognostic value in terms of recurrence-
free survival but a-catenin expression was not related to survival
(Crundwell et al, 1997). In the study by Richmond and co-workers
(Richmond et al, 1997) a-catenin was an important prognostic
factor only in the univariate analysis. Umbas et al (1997) also
observed that a-catenin was a predictor of patient outcome in
advanced disease and recurrence-free survival in radically treated
local tumours. However, they have not described the accuracy of
preoperative TNM in comparison to final post-operative pTNM
classification. Although the disease progression was associated
with abnormal a-catenin expression, the question still remains
whether  a-catenin is an independent predictor of progression. The
data in localized renal cell carcinoma suggest that a-catenin,
indeed, seems to have independent prognostic value (Shimazui
et al, 1997).
In conclusion, abnormal a-catenin expression is related to
advanced disease stages and malignant cellular features in prostate
cancer and the analysis of a-catenin expression may give addi-
tional prognostic information in M0 prostate cancer.
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